Olema Pharmaceuticals Company Insiders
OLMA Stock | USD 4.60 0.06 1.29% |
About 93 percent of Olema Pharmaceuticals' insiders are activelly selling. The analysis of the overall insider sentiment regarding Olema Pharmaceuticals suggests that a very large number of insiders are panicking. Olema Pharmaceuticals employs about 87 people. The company is managed by 16 executives with a total tenure of roughly 203 years, averaging almost 12.0 years of service per executive, having 5.44 employees per reported executive.
Insider Sentiment 7
Mostly Selling
Selling | Buying |
Latest Trades
2025-01-08 | Bain Capital Life Sciences Inv | Acquired 300000 @ 5.76 | View | ||
2024-12-17 | G. Walmsley Graham | Disposed 700761 @ 6.75 | View | ||
2024-12-10 | Sean Bohen | Disposed 52328 @ 9.37 | View | ||
2024-08-01 | Biocapital Advisors L Paradigm | Disposed 2400000 @ 14.91 | View | ||
2024-07-29 | Cyrus Harmon | Disposed 4066 @ 15.58 | View | ||
2024-07-11 | Cyrus Harmon | Disposed 5000 @ 12.26 | View | ||
2024-06-28 | Cyrus Harmon | Disposed 20000 @ 10.77 | View | ||
2024-06-03 | Cyrus Harmon | Disposed 5000 @ 10.93 | View | ||
2024-05-31 | Cyrus Harmon | Disposed 15000 @ 9.41 | View | ||
2024-05-06 | Cyrus Harmon | Disposed 5000 @ 10.92 | View | ||
2024-04-30 | Cyrus Harmon | Disposed 15000 @ 9.51 | View | ||
2024-03-28 | Cyrus Harmon | Disposed 20000 @ 10.97 | View | ||
2024-02-29 | Cyrus Harmon | Disposed 25000 @ 12.41 | View |
Monitoring Olema Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Olema |
Olema Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3315) % which means that it has lost $0.3315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5176) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals' management efficiency ratios could be used to measure how well Olema Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -0.33. The current year's Return On Capital Employed is expected to grow to -0.45. At present, Olema Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 8.7 M, whereas Total Assets are forecasted to decline to about 208 M.As of February 26, 2025, Common Stock Shares Outstanding is expected to decline to about 40 M. The current year's Net Loss is expected to grow to about (89.6 M)
Olema Pharmaceuticals Workforce Comparison
Olema Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,069. Olema Pharmaceuticals holds roughly 87.0 in number of employees claiming about 4% of equities under Health Care industry.
Olema Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Olema Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Olema Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Olema Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.6087 | 14 | 23 | 6,977,643 | 5,725,912 |
2024-06-01 | 1.2222 | 11 | 9 | 239,460 | 1,249,460 |
2024-03-01 | 0.8889 | 8 | 9 | 1,785,665 | 639,714 |
2023-12-01 | 0.5385 | 14 | 26 | 510,737 | 229,074 |
2023-09-01 | 0.8333 | 5 | 6 | 2,113,618 | 100,000 |
2023-06-01 | 3.0 | 9 | 3 | 182,160 | 20,000 |
2022-03-01 | 2.2 | 11 | 5 | 1,909,255 | 26,257 |
2021-12-01 | 0.5333 | 8 | 15 | 782,845 | 108,740 |
2021-09-01 | 0.35 | 7 | 20 | 20,753 | 77,506 |
2021-06-01 | 1.2 | 12 | 10 | 260,467 | 138,028 |
2020-12-01 | 1.0952 | 46 | 42 | 18,173,646 | 13,574,880 |
2020-09-01 | 5.5 | 11 | 2 | 3,316,948 | 135,525 |
Olema Pharmaceuticals Notable Stakeholders
An Olema Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Olema Pharmaceuticals often face trade-offs trying to please all of them. Olema Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Olema Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sasha CPA | VP Controller | Profile | |
JD Moriarty | Corporate Secretary | Profile | |
Peter Kushner | CoFounder Fellow | Profile | |
PharmD Faltaos | VP Pharmacology | Profile | |
Kinney Horn | Chief Officer | Profile | |
Cyrus Harmon | Chief Director | Profile | |
Courtney Dugan | VP Communications | Profile | |
John Moriarty | Chief VP | Profile | |
Moriarty ESQ | Corporate Secretary | Profile | |
Shane MBA | Chief Officer | Profile | |
Julie Dexter | Senior People | Profile | |
Courtney OKonek | Vice Communications | Profile | |
Naseem MD | Chief Officer | Profile | |
David Myles | Chief Officer | Profile | |
Geoffrey Mogilner | Vice Communications | Profile | |
Shawnte JD | Chief Secretary | Profile |
About Olema Pharmaceuticals Management Performance
The success or failure of an entity such as Olema Pharmaceuticals often depends on how effective the management is. Olema Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Olema management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Olema management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.31) | (0.33) | |
Return On Capital Employed | (0.47) | (0.45) | |
Return On Assets | (0.31) | (0.33) | |
Return On Equity | (0.44) | (0.42) |
Please note, the presentation of Olema Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Olema Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Olema Pharmaceuticals' management manipulating its earnings.
Olema Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Olema Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Olema Pharmaceuticals within its industry.Olema Pharmaceuticals Manpower Efficiency
Return on Olema Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 6M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 15.3M |
Complementary Tools for Olema Stock analysis
When running Olema Pharmaceuticals' price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |